All In Biotech

Drug Trial Radar · NCT07719855

A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 652 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

652

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Jul 2030

Study completion Dec 2033

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study intends to conduct a prospective, multicenter, open-label, randomized controlled clinical trial to systematically evaluate the efficacy and safety of the orelabrutinib plus obinutuzumab and lenalidomide (RO2) regimen versus the obinutuzumab-combined chemotherapy (O-chemo) regimen in patients with previously untreated follicular lymphoma. The primary observation is whether the RO2 regimen can maintain or improve therapeutic efficacy while significantly reducing hematological toxicities and other related adverse reactions, so as to provide a novel therapeutic option for improving the prognosis and quality of life of patients with follicular lymphoma (FL).

Conditions

  • Follicular Lymphoma ( FL)

Interventions

  • OrelabrutinibDrug

    Orelabrutinib PO will be administered as per the schedule specified in the respective arm.

  • obinutuzumabDrug

    Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

  • LenalidomideDrug

    Lenalidomide PO will be administered as per the schedule specified in the respective arm.

  • CyclophosphamideDrug

    Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.

  • DoxorubicinDrug

    Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.

  • PrednisoneDrug

    Prednisone PO will be administered as per the schedule specified in the respective arm.

  • VincristineDrug

    Vincristine infusion will be administered as per the schedule specified in the respective arm.

  • BendamustineDrug

    Bendamustine infusion will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survivalTime frame: From enrollment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (a maximum of 6 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hosiptal

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.